The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .
Effects of gemfibrozil on lipids and haemostasis after myocardial infarction.
The effects of gemfibrozil on haemostatic variables were studied in 43 survivors of myocardial infa rct ion with serum triglycerides ( TG ) greater than or equal to 2 mmol/l 2 weeks prior to r and omization . The study was double-blind , placebo-controlled and stratified for chronic betablockade . Twenty-two individuals were given gemfibrozil 600 mg twice daily and 21 individuals received matching placebo . After 8 weeks the TG level was unchanged in the placebo group , whereas a 44 % reduction was noted in the gemfibrozil group ( p less than 0.001 ) . Fibrinogen increased in both groups , while bleeding time and platelet count were unchanged . Clotting factor VII-phospholipid complex decreased in both groups , but the change was more marked and attained statistical significance only in the gemfibrozil group ( 60 % reduction , p less than 0.01 ) . By DDAVP-stimulated D-Dimer agglutination test 8 in 21 patients in the placebo group ( 38 % ) still had reduced fibronolytic capacity versus none in the gemfibrozil group ( p = 0.001 ) . Thus , in this study , gemfibrozil improved reduced fibrinolytic capacity and may have reduced hypercoagulability by lowering the clotting factor VII-phospholipid complex
The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .